Joseph W. Landry, Ph.D.
Research program member: Cancer Molecular Genetics
1101 E. Marshall St.
Richmond, VA 23298
Assistant Professor, Human and Molecular Genetics, School of Medicine
PhD, SUNY Stony Brook (2002)
We study epigenetic regulatory mechanisms of tumor cell immunogenicity. These mechanisms serve to suppress tumor cell immunogenicity, which in turn suppress the anti-tumor immune response. By studying these mechanisms, we hope to discover novel drug targets, which can be exploited as cancer therapies. Our current focus is on the chromatin remodeling factor NURF, which we have discovered to regulate both the adaptive and innate immune response to tumor cells.
Animal models,Cancer cell biology,Drug discovery,Epigenetics,Immunotherapy,Metabolism,Targeted therapies,Tumor microenvironment